Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 May 23;9:1114. doi: 10.3389/fimmu.2018.01114

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Shemesh, Kundu, Peleg, Yossef, Kaplanov, Ghosh, Khrapunsky, Gershoni-Yahalom, Rabinski, Cerwenka, Atlas and Porgador.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of R11-NLS-pep8 on 4T1 and B16 in vivo tumor models. (A) 4T1 cells or (C) B16 cells were injected into the nipple pad or flank of young BALB/C females or C57BL/6 males, respectively (day 0). At day 5, mice were divided to subgroups according to mice weight. Treatment was started at day 5 (4T1) or day 6 (B16) and end at day 22. Treatment was administrated every 2 days three times per week; 5-FU was administered intraperitoneally (IP) while R11-NLS-pep8 was administrated intravenously (4T1) or IP (B16). Tumor volume (mm³) was measured at days as indicated on graphs mean tumor volume (mm³), (B) 4T1 and (D) B16 were normalized to vehicle/day to show the effect of treatment on tumor volume per day. Statistical analysis was performed on original tumor volume data. Unpaired t-test; one-tail, *p < 0.05.